Table 1.
Demographic and clinical characteristics of prostate cancer patients by androgen deprivation therapy (ADT) exposure. Data are expressed as mean (SD) for continuous data or % of sample for categorical data.
| Characteristic | Current ADT (N=119) | Past ADT (N=62) | Never ADT (N=99) | p-value |
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | ||
| Age (yrs.) | 72.5 (7.8) | 72.9 (8.0) | 69.7 (7.6) | 0.01 |
| BMI (kg/m2) | 29.2 (4.8) | 29.0 (6.0) | 26.8 (3.9) | <0.01* |
| BMI category (%) | ||||
| Underweight & Normal | 17.5% | 29.0% | 29.3% | |
| Overweight | 41.6% | 30.6% | 54.5% | <0.01* |
| Obese | 40.8% | 40.3% | 16.2% | |
| Racea | ||||
| White | 91.7% | 98.4% | 97.0% | |
| African American | 2.5% | 0.0% | 1.0% | |
| Asian | 1.7% | 1.6% | 0.0% | |
| Native American/Alaskan Native | 0.8% | 0.0% | 0.0% | 0.58 |
| Native Hawaiian/Pacific Islander | 0.0% | 0.0% | 1.0% | |
| Hispanic (%) | 1.7% | 0.0% | 2.1% | 0.55 |
| Time since diagnosis (months) | 56.2 (53.2) | 71.0 (39.1) | 65.2 (41.2) | 0.10 |
| Disease severity | <0.01* | |||
| Loco-regional (%) | 56.3% | 87.1% | 86.9% | |
| Biochemical recurrence (%) | 13.4% | 11.3% | 13.1% | |
| Metastatic disease (%) | 30.3% | 1.1% | 0% | |
| Received surgery (%) | 36.1% | 37.7% | 81.6% | <0.01* |
| Received radiation therapy (%) | 75.8% | 85.5% | 26.3% | <0.01* |
| Received chemotherapy (%) | 9.3% | 5.1% | 2.0% | 0.07 |
*
p-value <0.001
a
Percentages do not add up to 100% due to some men identifying as “more than one race” or “other race”